BioNTech (NASDAQ:BNTX) CEO Sells 46,000 Shares of Stock

BioNTech SE Sponsored ADR (NASDAQ:BNTX) CEO Ugur Sahin sold 46,000 shares of the company’s stock in a transaction dated Tuesday, September 22nd. The shares were sold at an average price of $100.72, for a total transaction of $4,633,120.00. Following the completion of the sale, the chief executive officer directly owned 410,209 shares of the company’s stock, valued at $41,316,250.48. This represents a 10.08% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

• On Monday, September 21st, Ugur Sahin sold 33,000 shares of BioNTech stock. The stock was sold at an average price of $97.81, for a total value of $3,227,730.00.
• On Friday, September 18th, Ugur Sahin sold 30,000 shares of BioNTech stock. The shares were sold at an average price of $96.22, for a total value of $2,886,600.00.
• On Thursday, September 17th, Ugur Sahin sold 34,000 shares of BioNTech stock. The shares were sold at an average price of $98.60, for a total value of $3,352,400.00.
• On Wednesday, September 16th, Ugur Sahin sold 15,000 shares of BioNTech stock. The stock was sold at an average price of $96.09, for a total value of $1,441,350.00.
• On Tuesday, September 15th, Ugur Sahin sold 34,000 shares of BioNTech stock. The stock was sold at an average price of $96.49, for a total value of $3,280,660.00.
• On Monday, September 14th, Ugur Sahin sold 41,000 shares of BioNTech stock. The shares were sold at an average price of $99.45, for a total transaction of $4,077,450.00.
• On Friday, September 11th, Ugur Sahin sold 45,000 shares of BioNTech stock. The shares were sold at an average price of $96.93, for a total transaction of $4,361,850.00.
• On Thursday, September 10th, Ugur Sahin sold 20,500 shares of BioNTech stock. The stock was sold at an average price of $96.31, for a total transaction of $1,974,355.00.
• On Wednesday, September 9th, Ugur Sahin sold 36,000 shares of BioNTech stock. The shares were sold at an average price of $97.78, for a total transaction of $3,520,080.00.
• On Tuesday, September 8th, Ugur Sahin sold 37,000 shares of BioNTech stock. The shares were sold at an average price of $99.20, for a total transaction of $3,670,400.00.

BioNTech Trading Up 2.9%

Shares of BNTX stock traded up $2.87 during trading hours on Tuesday, hitting $100.87. The company had a trading volume of 1,050,346 shares, compared to its average volume of 1,100,679. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.85 and a quick ratio of 7.80. The stock has a market capitalization of $25.51 billion, a PE ratio of -12.88 and a beta of 1.29. The company’s fifty day moving average is $97.54 and its 200 day moving average is $94.82. BioNTech SE Sponsored ADR has a fifty-two week low of $79.52 and a fifty-two week high of $124.00.

BioNTech (NASDAQ:BNTX) last posted its earnings results on Tuesday, August 4th. The company reported ($2.53) earnings per share for the quarter, missing the consensus estimate of ($2.40) by ($0.13). BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. The company had revenue of $122.31 million during the quarter, compared to analyst estimates of $180.18 million. During the same quarter last year, the business posted ($1.60) EPS. The firm’s revenue for the quarter was down 59.5% on a year-over-year basis. Research analysts expect that BioNTech SE Sponsored ADR will post -6.37 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

BNTX has been the topic of several analyst reports. UBS Group reiterated a “buy” rating on shares of BioNTech in a research note on Wednesday, September 16th. Canaccord Genuity Group lowered their price target on BioNTech from $142.00 to $136.00 and set a “buy” rating for the company in a report on Monday, August 31st. Morgan Stanley cut their price objective on shares of BioNTech from $126.00 to $119.00 and set an “overweight” rating on the stock in a report on Wednesday, July 8th. Citigroup cut their price target on shares of BioNTech from $130.00 to $125.00 and set a “buy” rating on the stock in a research note on Wednesday, August 5th. Finally, BMO Capital Markets downgraded shares of BioNTech from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $128.00 to $105.00 in a research note on Tuesday, September 8th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $126.00.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of BNTX. Larson Financial Group LLC lifted its position in BioNTech by 86.4% during the 4th quarter. Larson Financial Group LLC now owns 274 shares of the company’s stock worth $26,000 after acquiring an additional 127 shares during the period. Integrated Wealth Concepts LLC purchased a new position in shares of BioNTech during the 2nd quarter worth approximately $39,000. Caitong International Asset Management Co. Ltd raised its stake in shares of BioNTech by 1,012.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 556 shares of the company’s stock worth $53,000 after buying an additional 506 shares in the last quarter. Vestcor Inc acquired a new stake in shares of BioNTech in the 4th quarter valued at approximately $153,000. Finally, Rockefeller Capital Management L.P. lifted its holdings in shares of BioNTech by 328.6% in the 4th quarter. Rockefeller Capital Management L.P. now owns 1,856 shares of the company’s stock valued at $177,000 after buying an additional 1,423 shares during the period. 15.52% of the stock is currently owned by institutional investors and hedge funds.

BioNTech Company Profile

BioNTech SE is a biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. Its research platforms include messenger RNA, cell therapies, protein-based therapeutics, antibody therapies and small-molecule immunomodulators.

The company is best known for Comirnaty, its COVID-19 vaccine developed and commercialized globally in collaboration with Pfizer. BioNTech is also advancing a broad oncology pipeline that includes individualized and off-the-shelf cancer vaccines, antibody-based treatments, cell therapies and combination approaches designed to stimulate or direct the immune system against tumors.

BioNTech was founded in 2008 and is headquartered in Mainz, Germany.